Iga Świątek and the Contaminated Melatonin: Strict Liability, Secrecy and Consistency

Timeline

1. Aug 12, 2024Świątek provides an out-of-competition urine sample that later shows a low level of trimetazidine.
2. Sep 12, 2024The ITIA issues a pre-charge notice and a mandatory provisional suspension.
3. Sep 22, 2024Świątek appeals the provisional suspension to an independent tribunal chair.
4. Sep 26, 2024Her lawyers identify a Polish melatonin product as the likely source.
5. Oct 4, 2024A WADA-accredited lab in Utah confirms TMZ in tablets from the same batch; the provisional suspension is lifted.
6. Nov 27, 2024Świątek admits the violation and accepts a one-month ban.
7. Nov 28, 2024The ITIA announces the case; Halep and the PTPA criticize the system.
8. Nov 29–Dec 2, 2024Poland's pharmaceutical inspectorate announces and carries out an unannounced inspection of the melatonin manufacturer.
9. Dec 4, 2024The ban expires.
10. Jan 20, 2025WADA announces it will not appeal.

The ethical issues

• Strict liability: an athlete is responsible for any banned substance in her body, even from a contaminated medicine.
• Confidentiality vs. transparency: a provisional suspension was kept private, and the public was told she was missing events for personal reasons.
• Consistency: different outcomes for similar contamination claims fuel perceptions of a two-tier system.
• Resources and access: rapid, expert-backed defense may be easier for top-ranked, well-funded players.
• Proportionality: how much fault attaches to taking a regulated medicine without batch testing.

Stakeholders

Stakeholder	Interests & obligations
Iga Świątek	Her reputation, eligibility and the fairness of the process.
Other players	Equal treatment, clean competition and access to due process regardless of ranking.
International Tennis Integrity Agency	A credible, Code-compliant anti-doping program.
WADA	Consistent application of the World Anti-Doping Code worldwide.
WTA and tournaments	Integrity of competition and the image of star players.
Fans and sponsors	Trust in the sport's results and honest public communication.

The case

In September 2024, Iga Świątek, the world’s top-ranked women’s tennis player, withdrew from the Korea Open. Her team cited “personal reasons.” The real reason became public only in late November: she had tested positive for a banned heart medication, had been provisionally suspended and had missed three tournaments. By the time fans learned of it, she had shown the drug came from contaminated sleep medication and had accepted a one-month ban, most of which she had already served.^[1][5]

Background

Świątek, from Poland, was a five-time Grand Slam champion and the reigning French Open champion when the case was announced. She was world No. 1 when she was tested in August 2024 and No. 2 when the ban was announced.^[1][3]

The case came months after men’s No. 1 Jannik Sinner was cleared of fault for two positive tests for the steroid clostebol, a decision WADA was appealing. Players on both tours had already complained of what they saw as double standards. Former world No. 1 Simona Halep, meanwhile, had been provisionally suspended in October 2022 for the anemia drug roxadustat, banned for four years in September 2023, and had that ban cut to nine months by the Court of Arbitration for Sport (CAS) in March 2024. She had argued that a contaminated supplement was to blame.^[4]

The rules and governance

The ITIA runs tennis’s anti-doping program under rules that implement the World Anti-Doping Code. The presence of a prohibited substance is a strict liability violation: the ITIA does not have to prove how it got there or that the athlete meant to take it. TMZ, a “hormone and metabolic modulator,” is a non-specified substance, so a positive test triggers a mandatory provisional suspension. The standard ban for an unintentional violation is two years.^[1][2]

An athlete can reduce the ban by showing “No Fault or Negligence” (which eliminates it) or “No Significant Fault or Negligence” (which allows a reduction, potentially to zero when the substance came from a contaminated product). The Code says the first cannot succeed for a contaminated supplement, because athletes have been warned of that risk. Under tennis rules, a provisional suspension successfully appealed within 10 days of notice is not publicly disclosed.^[1][2]

The positive test and the search for a source

Świątek gave an out-of-competition urine sample on August 12, 2024. It contained TMZ at an estimated 50 picograms per milliliter. On September 12, the ITIA sent her a pre-charge notice and imposed a provisional suspension. She missed the Korea Open, the China Open and, because she was suspended at its entry deadline, the Wuhan Open.^[1][2]

She appealed the suspension on September 22. Late on September 26, her lawyers reported that a melatonin product she used, LEK-AM Melatonina 1 mg, a non-prescription medicine regulated and sold in Polish pharmacies, had tested positive for TMZ in laboratories in Paris and Strasbourg. She said her physician had recommended it for jet lag, and that she had taken two or three tablets at about 2 or 3 a.m. on August 12 when she could not sleep, a few hours before testers arrived. She had listed 14 supplements and medications on her doping control form but not the melatonin, which she said she forgot because she was tired and it was not on the list she copied from. The ITIA called that omission “unsatisfactory” but accepted her explanation.^[2]

The ITIA insisted on independent verification. The Sports Medicine Research and Testing Laboratory in Salt Lake City, a WADA-accredited lab, analyzed the remains of her opened container and a sealed container from the same batch. On October 4, it reported TMZ in tablets from both, with the highest concentrations inside the crushed pills, suggesting contamination during manufacture. The manufacturer did not respond to the ITIA, which noted that the company also makes a TMZ product. Two laboratory directors found her account scientifically plausible. Negative samples taken at the Olympics in early August and at the U.S. Open on August 27, plus negative hair tests, were consistent with contamination rather than therapeutic use. The ITIA stopped opposing her appeal, and the suspension was lifted the same day.^[1][2]

The sanction

The ITIA concluded that she could not claim No Fault or Negligence. Melatonin is a dietary supplement in some countries, including the United States, and batch-tested melatonin products were available. Treating a product differently because one country classifies it as a medicine, the decision said, “would risk creating significant inequality in the way athletes from different countries were treated by the rules.” But it accepted that her fault was not significant and placed it “at the lowest end” of that range. It proposed a one-month ban, longer than some U.S. cases involving contaminated prescription drugs but shorter than an earlier ITIA case involving a contaminated TMZ supplement. Świątek accepted on November 27. With credit for the provisional suspension already served, eight days remained, ending December 4, 2024. She forfeited her prize money from the Cincinnati Open, the tournament right after the test, but kept her later results, including the U.S. Open.^[1][2]

“This case is an important reminder for tennis players of the strict liability nature of the World Anti-Doping Code,” said ITIA chief executive Karen Moorhouse.^[1] Świątek said the “only positive doping test in my career, showing unbelievably low level of a banned substance I’ve never heard about before, put everything I’ve worked so hard for my entire life into question.”^[3]

Reaction

Halep responded on Instagram: “I stand and ask myself, why is there such a big difference in treatment and judgment? I can’t find and I don’t think there can be a logical answer.” She accused the ITIA of “bad will.” The Professional Tennis Players Association said players “deserve and are entitled to due process and support in navigating the anti-doping system, regardless of ranking and access to resources.” Moorhouse said, “These aren’t cases of intentional doping. We’re dealing with inadvertent breaches of the rules.”^[4]

The manufacturer and the regulator

The case also reached Poland’s medicines regulator. On November 29, 2024, the day after the ban was announced, the Chief Pharmaceutical Inspectorate (GIF) said the manufacturer named in media reports made medicines containing both melatonin and trimetazidine. It had received no reports of a suspected quality defect, but said it would treat the press reports as one and carry out an unannounced inspection of the production site “to confirm or rule out a quality defect.”^[7] The inspection ended on December 2. According to the manufacturer, LEK-AM, inspectors reviewed cleaning procedures for production equipment and hygiene rules at its plant in Zakroczym and found no critical or major nonconformities; the company said a quality defect had been ruled out and that the trace TMZ detected was “significantly below acceptable limits” (in translation) and posed no risk to patients.^[8]

Aftermath

On January 20, 2025, WADA said it would not appeal. It had received the case file on November 29 and reviewed it in full. Its scientific experts confirmed that “the specific contaminated melatonin scenario” was plausible and that there would be “no scientific grounds to challenge it” at CAS, and external counsel advised that the explanation was “well evidenced” and the ITIA decision compliant with the Code.^[6]

Świątek later described the period as “probably, like, the worst time in my life” and explained the “personal reasons” statement: “we honestly thought the suspension is going to be lifted soon.”^[5]

The core dilemma

Świątek appears to have done nothing intentionally wrong, yet strict liability made her responsible for a contaminated pill. The system gave her a short ban and kept her suspension confidential while she proved her case. Both features can be defended as fair to her. But to other players and fans, a quiet resolution for a star, set against long, public ordeals for others, looked like inconsistency. How should anti-doping systems balance individual fairness, privacy and public trust?

Competing values

• Strict liability vs. individual blamelessness: certainty for the system, hardship for the inadvertent.
• Privacy vs. transparency: confidentiality protects athletes who may be cleared, but “personal reasons” misled the public.
• Case-by-case justice vs. consistency: different facts justify different outcomes, but the reasons must be visible.
• Equal rules vs. unequal resources: everyone faces the same Code, but not everyone can commission laboratory tests within days.

Strongest arguments

For the outcome: the evidence was unusually strong, including independent lab confirmation from a sealed container of the same batch, negative samples on either side and a substance level consistent with contamination. Confidentiality for successfully appealed provisional suspensions is a rule that applies to everyone. WADA, which appealed Sinner’s case, reviewed this one and declined.

For concern: the public was told something untrue while a top player was suspended. Halep’s case, which also involved a claimed contaminated product, took far longer to resolve. Whatever the facts, the gap feeds a perception that wealthier, higher-ranked players move through the system faster.

On strict liability itself: some argue a one-month ban for taking a regulated medicine as recommended by a doctor is still unjust; others reply that without strict liability, contamination claims would become an easy excuse.

Applying the frameworks

Justice & fairness

A justice lens asks whether like cases are treated alike. The ITIA explicitly reasoned about consistency, refusing to give a “medication” special status that would favor athletes from some countries. But procedural justice also asks whether every player has the same practical access to rapid testing and expert counsel. Behind a veil of ignorance, players might accept strict liability but demand equal support to rebut it.

Rights-based

A rights lens weighs Świątek’s rights to privacy and due process against the public’s and competitors’ interest in knowing. Keeping a provisional suspension confidential protects an athlete who may be cleared from lasting reputational harm. The question is whether that right extends to offering a misleading public explanation.

Utilitarian

A utilitarian would ask which system produces the best overall results. Strict liability deters cheating and avoids endless disputes over intent. Short bans for genuine contamination limit harm to innocent athletes. But if fans and players come to believe the system is inconsistent, its deterrent and legitimating value erodes.

Walk it through: the Simple Decision Model

1. Spot the issue. You are the ITIA’s head of communications in September 2024, knowing the world No. 1 is provisionally suspended and has appealed within 10 days. Stakeholders include Świątek, other players, tournaments, WADA, fans and the media. The codes in play are the Tennis Anti-Doping Programme and the World Anti-Doping Code.
2. Gather facts. What do the rules require you to disclose, and when? What is the player’s team saying publicly? How have similar cases been communicated? Watch for the bias of treating a star’s case as different.
3. Test options. Options: (a) follow the confidentiality rule and say nothing; (b) say nothing but ask the player’s team not to give misleading reasons; (c) propose a rule change requiring disclosure of all provisional suspensions. Weigh harm to an athlete who may be cleared against harm to trust.
4. Check codes and law. Confirm the 10-day non-disclosure provision and privacy obligations. Consider how the Code expects provisional suspensions to be handled.
5. Decide and document. Record why the case was handled as it was, so you can explain it when the decision is published.
6. Communicate and follow up. When announcing the outcome, explain the confidentiality rule and how it applies to all players, and publish the full reasoning so others can compare cases.

What’s settled and what’s contested

• Settled: the positive test, the independent laboratory findings, the one-month ban ending December 4, 2024 and WADA’s decision not to appeal.
• Contested: whether any fault should attach to a regulated medicine; whether the confidentiality rule and the “personal reasons” explanation were appropriate; and whether Świątek’s and Halep’s cases were handled consistently, which Halep disputes and the ITIA defends.

Why this case matters

Contamination cases are where strict liability is hardest to defend and easiest to doubt. The Świątek case shows a system working as designed, with independent science and published reasoning, yet still struggling to win trust when outcomes differ and information arrives late. For any sport, the lesson is that fairness must be visible as well as real.

See also: Twenty-Three Chinese Swimmers, Trimetazidine, and Trust in WADA.

Key terms

Strict liability

The anti-doping principle that athletes are responsible for any prohibited substance in their bodies, whether or not they meant to take it.

Due process

Fair procedures before a sanction: notice, a chance to respond, an impartial decision-maker and a right of appeal.

Trust

The public’s belief that what they are watching is real. Integrity failures are ultimately failures of trust.

Fair play

Integrity put into practice: respecting both the written rules and the spirit of competition.

Codes and guardrails

Written rules of conduct, backed by real consequences, that turn values into expected behavior. Without enforcement they are decoration.

Multiple points of view

Analyzing a dilemma from each stakeholder’s position in turn (athlete, parent, coach, administrator, official, bystander) before reaching your own reasoned view.

Definitions from the Ethics Cases glossary.

Discussion questions

1. Should an athlete bear any fault for a contaminated product that is a regulated medicine in her country?
2. Was it right that Świątek's provisional suspension was not made public, and that her absence was attributed to 'personal reasons'?
3. Halep's and Świątek's cases produced very different outcomes. What facts would justify the difference, and what would make it unjust?
4. Does the strict liability system favor players who can afford rapid laboratory testing and expert counsel?
5. How should tennis balance athlete privacy with public confidence in its anti-doping program?

Sources

1. Polish tennis player Iga Świątek accepts one-month suspension under Tennis Anti-Doping Programme — International Tennis Integrity Agency
2. ITIA v Świątek: Decision (Nov. 27, 2024) — International Tennis Integrity Agency
3. 'Toughest battle in my life' - Swiatek accepts one-month doping ban — BBC Sport
4. Simona Halep questions handling of her doping case after Iga Swiatek ban — ESPN (Reuters)
5. WADA won't lodge appeal in Iga Swiatek doping case — ESPN
6. WADA will not appeal in case of tennis player Iga Świątek (Jan. 20, 2025) — World Anti-Doping Agency
7. Informacja Głównego Inspektoratu Farmaceutycznego z dnia 29.11.2024 r. (in Polish) — Główny Inspektorat Farmaceutyczny (Poland's Chief Pharmaceutical Inspectorate)
8. Melatonina LEK-AM bezpieczna dla zdrowia pacjentów. Wykluczona wada jakościowa produktu (in Polish) — LEK-AM (manufacturer press release)